A Cayuela1, L Cayuela2, M V Ruiz-Romero3, S Rodríguez-Domínguez4, G Lendínez-Cano5, J Bachiller-Burgos5. 1. Unidad de Gestión Clínica de Salud Pública, Prevención, Promoción y Vigilancia de la Salud, Hospital de Valme, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España. Electronic address: aurelio.cayuela.sspa@juntadeandalucia.es. 2. Facultad de Medicina, Universidad de Sevilla, Sevilla, España. 3. Servicio de Atención al Usuario y Calidad, Consorcio Sanitario Público del Aljarafe, Hospital San Juan de Dios del Aljarafe , Bormujos, Sevilla, España. 4. Centro de Salud Pino Montano A, Distrito Sanitario Sevilla, Sevilla, España. 5. Servicio de Urología, Consorcio Sanitario Público del Aljarafe, Hospital San Juan de Dios del Aljarafe, Bormujos, Sevilla, España.
Abstract
OBJECTIVE: To describe the evolution of prostate cancer mortality in Spain during the period 1980-2013. SUBJECT AND METHOD: The prostate cancer mortality data and population data needed to calculate the indicators were provided by the National Institute of Statistics. We calculated the specific rates by age group, raw and standardised globally using the direct method (European standard population). The rates are expressed for 100,000 person-years. For the analysis of trends in the rates, we used joinpoint regression models. RESULTS: The overall rates adjusted for age in Spain decreased from 21.7 to 15.4 deaths per 100,000 men-years between the starting and ending date of the study period (annual percentage change: -.9%; P<.05). The joinpoint analysis reflects 2 periods: 1980-1998 (.7% annual increase; P<.05) and 1998-2013, during which the rates decreased significantly (-3%; P<.05). Except for the autonomous cities of Ceuta and Melilla where the rates remained stable over the course of the study period, the communities showed 1 or 2 points of inflection in the trends, and all had a final period with a reduction in the rates (except for Galicia and Catalonia, where the rates stabilised in 2008-2013). CONCLUSION: The decline in prostate cancer mortality in Spain appears to have stopped in Galicia and Catalonia.
OBJECTIVE: To describe the evolution of prostate cancer mortality in Spain during the period 1980-2013. SUBJECT AND METHOD: The prostate cancer mortality data and population data needed to calculate the indicators were provided by the National Institute of Statistics. We calculated the specific rates by age group, raw and standardised globally using the direct method (European standard population). The rates are expressed for 100,000 person-years. For the analysis of trends in the rates, we used joinpoint regression models. RESULTS: The overall rates adjusted for age in Spain decreased from 21.7 to 15.4 deaths per 100,000 men-years between the starting and ending date of the study period (annual percentage change: -.9%; P<.05). The joinpoint analysis reflects 2 periods: 1980-1998 (.7% annual increase; P<.05) and 1998-2013, during which the rates decreased significantly (-3%; P<.05). Except for the autonomous cities of Ceuta and Melilla where the rates remained stable over the course of the study period, the communities showed 1 or 2 points of inflection in the trends, and all had a final period with a reduction in the rates (except for Galicia and Catalonia, where the rates stabilised in 2008-2013). CONCLUSION: The decline in prostate cancer mortality in Spain appears to have stopped in Galicia and Catalonia.